Fibroblast Growth Factor-21 Predicts Outcome in Community-Acquired Pneumonia Secondary Analysis of two Randomized Controlled Trials.

Ebrahimi, Fahim; Wolffenbuttel, Carole; Blum, Claudine A; Baumgartner, Christine; Mueller, Beat; Schuetz, Philipp; Meier, Christian; Kraenzlin, Marius; Christ-Crain, Mirjam; Betz, Matthias Johannes (2019). Fibroblast Growth Factor-21 Predicts Outcome in Community-Acquired Pneumonia Secondary Analysis of two Randomized Controlled Trials. European respiratory journal, 53(2) European Respiratory Society 10.1183/13993003.00973-2018

[img] Text
Ebrahimi, Eur J Respir 2018.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Acute systemic inflammatory conditions come along with profound alterations of metabolism. However the role of FGF21, a recently identified central regulator of metabolism is largely unknown in community-acquired pneumonia.This study aims to characterise the pattern of FGF21 in pneumonia and associations with disease severity and outcome.This is a secondary analysis of two independent multicenter randomised controlled trials in patients presenting to the emergency department with community-acquired pneumonia. Primary and secondary efficacy parameters included 30-day mortality, length of hospital stay, time to clinical stability and duration of antibiotic treatment.A total of 509 patients were included in the analysis. FGF21 levels at admission strongly correlated to disease severity, as measured by pneumonia severity index. Increased levels of FGF21 were associated with prolonged time to clinical stability, antibiotic treatment and hospitalisation. FGF21 levels at admission were significantly higher in non-survivors than in survivors, yielding a 1.61-fold increased adjusted odds ratio of 30-day mortality (95% CI, 1.21-2.14; p=0.001). Moreover, FGF21 was found to identify patients for 30-day mortality with superior discriminative power compared to than routine diagnostic markers.In moderate-to-severe CAP patient with higher levels of FGF21 were at increased risk for clinical instability, prolonged hospitalisation and 30-day all-cause mortality.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine

UniBE Contributor:

Baumgartner, Christine

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0903-1936

Publisher:

European Respiratory Society

Language:

English

Submitter:

Christine Baumgartner

Date Deposited:

21 Jan 2019 13:28

Last Modified:

21 Nov 2019 04:52

Publisher DOI:

10.1183/13993003.00973-2018

PubMed ID:

30578395

BORIS DOI:

10.7892/boris.123225

URI:

https://boris.unibe.ch/id/eprint/123225

Actions (login required)

Edit item Edit item
Provide Feedback